linjc16/ctgov huggingface dataset:
A Comparative Study of Proton-pump Inhibitor Tests for Chinese Reflux Patients in Relation to the CYP2C19 Genotypes

Study Overview
=================
Brief Summary
-----------------
Backgrounds & Aims: Proton-pump inhibitor (PPI) test has been proposed as a valuable tool in the diagnosis of gastroesophageal reflux disease (GERD) in Western populations. We assumed that a higher prevalence of poor metabolizers in Chinese population might affect the diagnostic accuracy of a PPI test. Methods: In this open-label, randomized trial, patients with symptoms suggestive of GERD were randomly assigned to receive a 2-week test with daily rabeprazole 40-mg or daily pantoprazole 80-mg after diagnostic endoscopy. Therapeutic response was assessed with a five-grade daily record. Genotypes of cytochrome P450 (CYP) 2C19 polymorphism were determined.

Detailed Description
-----------------
As described above

Official Title
-----------------
A Comparative Study of Proton-pump Inhibitor Tests for Chinese Reflux Patients in Relation to the CYP2C19 Genotypes

Conditions
-----------------
GERD

Intervention / Treatment
-----------------
* Drug: rabeprazole
* Drug: pantoprazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consecutive patients with symptoms suggesting GERD will be enrolled from gastroenterology outpatient clinics in our academic institute. The typical GERD symptom was defined as heartburn and/or regurgitation at least 3 episodes per week in recent 3 months. Exclusion Criteria: Those who were under maintenance PPI treatment, have a medical contraindication to PPI therapy, report a history of peptic ulcer disease or gastrointestinal surgery, malignancy proven by endoscopy, or unwilling or unable to provide informed consent.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Rabeprazole<br>Rabeprazole 1 # qd | Drug: rabeprazole<br>* 20 mg bid for 14 days<br>* Other names: Pariet;|
| Active Comparator: pantoprazole<br>Pantoprazole 1# qd | Drug: pantoprazole<br>* pantoprazole 40 mg bid<br>* Other names: Pantoloc;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| at least 50% reduction of symptoms |  | 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PPI test, gastroesophageal reflux disease, CYP2C19, rabeprazole, pantoprazole
Chondromodulating Effect of Diacerein in Osteoarthritis of the Hip

Study Overview
=================
Brief Summary
-----------------
We carried out a 3 years, randomized, double-blind, placebo-controlled, multicenter clinical trial in patients with hip osteoarthritis in order to: evaluate the ability of diacerein, an interleukin-1β inhibitor, to slow the progressive decrease in joint space width observed in patients with hip osteoarthritis to investigate the potential structure-modifying effect of diacerein in patients with hip osteoarthritis This study compare also after ten years the percentage of patients in each treatment group who require a hip replacement surgery

Official Title
-----------------
Evaluation of the CHOndromodulating Effect of DIAcerein in Osteoarthritis of the Hip. ECHODIAH.

Conditions
-----------------
Hip Osteoarthritis

Intervention / Treatment
-----------------
* Drug: diacerein


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Outpatients fulfilling the American College of Rheumatology criteria for the diagnosis of hip osteoarthritis. Lequesne algofunctional index of at list 3 points. Radiographic criterion for inclusion: joint space width (JSW) between 1 mm and 3 mm. If the JSW exceeded 3 mm, it had to be at least 0.5 mm thinner than JSW of the contra lateral hip, measured at its narrowest point. Exclusion Criteria: Intraarticular injection or arthroscopy of the hip during the three months prior to inclusion in the study. Any systemic or intraarticular corticosteroid as well as other potential symptom-modifying drugs for osteoarthritis were not allowed during the study.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: diacerein|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Joint space measurement |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Requirement of hip replacement surgery after ten years |  |  | 
| Tolerability |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Double blind study, Diacerein, Hip osteoarthritis, Structure-modifying effect / Chondromodulating effect
A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.

Study Overview
=================
Brief Summary
-----------------
The aim of this trial is to evaluate the safety and virological and immunological efficacy of Aptivus in treatment-experienced patients with advanced HIV-1 infection who had developed resistance to more than one protease inhibitor.

Official Title
-----------------
A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Tipranavir (Aptivus®) Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Tipranavir
* Drug: ritonavir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: HIV-1 infected patients who are treatment experienced and infected with HIV-1 strains resistant to more than one protease inhibitor and no other therapeutic options. The inclusion criteria follow the same criteria which are describe in the newest SPC Exclusion criteria: The exclusion criteria follow the same criteria which are describe in the newest SPC

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with HIV-1 infection<br> | Drug: Tipranavir<br> <br> Drug: ritonavir<br>* low-dose<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Patients Reporting Adverse Events (AE) | Any type of adverse events | 48 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Virologic Response | Virologic response is defined as HIV viral load of < 50 copies/mL before week 48 and without subsequent rebound or change of ARV therapy prior to week 48. A rebound is defined by two consecutive measurements of VL >= 50 copies/ml, at least two weeks apart, after two consecutive measurements of VL< 50 copies/ml. Because of many missing data concerning the viral load, the virologic response could be determined only for four patients. | 48 weeks | 
| Change in CD4+ Cell Count From Baseline at Week 48 |  | 48 weeks |
Pharmaceutical Care and Clinical Outcomes for the Elderly Taking Potentially Inappropriate Medication

Study Overview
=================
Brief Summary
-----------------
The investigators propose that clinical pharmacist interventions would reduce the rate of adverse drug events in elderly patients taking potentially inappropriate medication.

Official Title
-----------------
Pharmaceutical Care and Clinical Outcomes for the Elderly Taking Potentially Inappropriate Medication: a Randomized-Controlled Trial

Conditions
-----------------
Elderly, Chronic Disease

Intervention / Treatment
-----------------
* Behavioral: Pharmacist intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitalized patients aged at least 65 years Taking at least six prescribed medicines regularly, including at least one potential inappropriate medication Exclusion Criteria: Patients who refused informed consent Discharged before consent could be obtained Cognitive impaired

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pharmacist intervention<br>Patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including medication review, medication reconciliation, patient education and recommended actions. | Behavioral: Pharmacist intervention<br>* Medication review, medication reconciliation, and pharmacotherapy recommendation.<br>|
| No Intervention: Usual care<br>Patients randomized to usual care group will receive routine review of medication by ward-based pharmacist and nurse. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of unsolved drug-related problems |  | 14 days after randomization | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of adverse drug event during hospitalization |  | 14 days after randomization | 
| Number of potentially inappropriate medication |  | 14 days after randomization | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adverse drug reaction, Inappropriate medication, Pharmacist, Pharmaceutical care
Clinical Audit of Cardio Pulmonary Resuscitation Management in Adults Patient Units of Care by in Situ Simulation

Study Overview
=================
Brief Summary
-----------------
Clinical audit of in-hospital cardiac arrest management by in situ simulation Objectives: correct latent safety threats, knowledge gap, and crisis resource management (CRM) Design: clinical audit, observational sudy. Primary outcome: In Hospital resuscitation scale. Exploratory outcomes: non technical skills, validated stress inventory, and questionnaire on perceptions of the simulation and organisational changes needed.

Official Title
-----------------
Clinical Audit of Cardio Pulmonary Resuscitation Management in Adults Patient Units of Care by in Situ Simulation

Conditions
-----------------
in Hospital Cardiac Arrest, in Situ Simulation, Clinical Audit, Education

Intervention / Treatment
-----------------
* Other: cardio-pulmonary resuscitation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: team members: nurses, auxiliary nurses, residents, doctors, students Exclusion Criteria: non volunteers

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: cardio-pulmonary resuscitation|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In-Hospital resuscitation scale |  | 5 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ANTS scale |  | 5 months | 
| Peritraumatic Dissociative Experiences Questionnaire (PDEQ) | validated stress inventory | 5 months | 
| Peritraumatic Distress Inventory (PDI) | validated stress inventory | 5 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
in hospital cardiac arrest, in situ simulation, clinical audit, education
The Influence of Expectations on Patient Satisfaction in the Pediatric Emergency Department

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether physician knowledge of parental pre-visit expectations improves patient satisfaction in the pediatric emergency department.

Conditions
-----------------
Patient Satisfaction

Intervention / Treatment
-----------------
* Behavioral: Physician knowledge of parental expectations for the visit


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Parent of child less than or equal to 18 years of age Exclusion Criteria: Inability to understand the English language surveys

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Physician knowledge of parental expectations for the visit|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient satisfaction as measured by: |  |  | 
| 1. ratings of overall care |  |  | 
| 2. willingness to recommend the ED |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ratings of degree to which expectations were met |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Patient satisfaction, Patient expectations, Pediatric emergency department
The Effect of Lifestyle-Adjustments Prior to Medical Treatment on the Effect of Medical Treatment in Reflux Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the improvement in the quality of life after an initial treatment with esomeprazole 40mg for reflux disease is the same in patients who have already made lifestyle-adjustments as in patients who have not implemented lifestyle-adjustments prior to the start of treatment (baseline)

Conditions
-----------------
GERD, Quality of Life

Intervention / Treatment
-----------------
* Drug: esomeprazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with reflux complaints 18 years of age Exclusion Criteria: Restrictions as mentioned in the registration text H2RA or PPI use in the month prior to inclusion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: esomeprazole|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Patients with reflux complaints, GERD, quality of life, lifestyle adjustments
QOL in Incarcerated Inguinal Hernias: TAPP Vs Open Repair

Study Overview
=================
Brief Summary
-----------------
To determine if there is a difference in the quality of life in between patients who undergoes laparoscopic transabdominal pre-peritoneal (TAPP) or modified Lichtenstein hernioplasty

Detailed Description
-----------------
Patients presenting with incarcerated inguinal hernias will be randomized between open or laparoscopic repair groups. The primary outcome will be the quality of life scores. Patients will be followed-up for 12 months.

Official Title
-----------------
The Comparison of the Quality of Life and Outcomes in Patient's With Incarcerated Inguinal Hernias: Laparoscopic Transabdominal Pre-peritoneal (TAPP) Versus Modified Lichtenstein Hernioplasty

Conditions
-----------------
Inguinal Hernia

Intervention / Treatment
-----------------
* Procedure: Open modified Lichtenstein repair
* Procedure: Laparoscopic TAPP inguinal hernia repair


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age and older Both genders Unilateral inguinal hernias Incarcerated inguinal hernias Elective setting Exclusion Criteria: Anaesthesiologists) Grade > 2 Recurrence Inguinal-scrotal hernias Prostatectomy, Pfannenstiel incision, previous pre-peritoneal surgery Pregnancy Refusal for general anaesthesia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Open modified Lichtenstein repair<br> | Procedure: Open modified Lichtenstein repair<br>* Open Lichtenstein Hernioplasty<br>|
| Active Comparator: Laparoscopic TAPP inguinal hernia repair<br> | Procedure: Laparoscopic TAPP inguinal hernia repair<br>* Laparoscopic TAPP Hernioplasty<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life scores as measured by Carolinas Comfort Scale | Carolina Comfort Scale during the duration of follow-up | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Operating Time in Minutes | Comparing the duration of operation between open and laparoscopic surgeries. | 12 months | 
| Duration of Hospitalization in Days | Comparing the duration of post operative stay between open and laparoscopic surgeries. | 12 months | 
| Recurrence of Hernia after Operation | Comparing the recurrences between open and laparoscopic surgeries. | 12 monthts |
The Clinical Utility of QuantiFERON in the Diagnosis of Active Tuberculosis

Study Overview
=================
Brief Summary
-----------------
The investigators will evaluate the usefulness of QuantiFERON-TB Gold in-tube (QFT) in the diagnosis of active tuberculosis in young adults group, highly clinically suspected tuberculosis.

Detailed Description
-----------------
Investigators will enroll prospectively all clinically and radiologically suspected tuberculosis patients from 20 to 29 years old who visited the Armed Forces Capital Hospital. Investigators will perform QFT and tuberculin skin test. Diagnosis of tuberculosis will be made by World Health Organization guideline and the physician will not know the QuantiFERON-TB Gold in-tube results before the diagnosis and anti-tuberculosis medication. Investigators will evaluate the sensitivity and specificity of QuantiFERON-TB Gold in-tube in the diagnosis of active tuberculosis among young adults.

Official Title
-----------------
The Clinical Utility of QuantiFERON in the Diagnosis of Active Tuberculosis Among Young Adults

Conditions
-----------------
Tuberculosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All clinically and radiologically suspected TB patients from 20 to 29 years old who visited the Armed Forces Capital Hospital Exclusion Criteria: Soldiers who do not agree with study protocol
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TB suspected<br>Soldiers who are clinically suspected with tuberculosis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tuberculosis, pneumonia, QuantiFERON-TB Gold in-tube, Tuberculin skin test